Mainland approves nasal COVID vaccine co-developed by HKU
Mainland authorities have approved a nasal spray COVID-19 vaccine co-developed by the University of Hong Kong (HKU) for emergency use.
The nasal vaccination, created by HKU in partnership with Xiamen University and Wantai Pharmaceutical, is over 80% effective against the Omicron variants for those who are vaccinated, according to a statement from a HKU representative.
However, it only has a 55 percent effectiveness for people who are unvaccinated.
The spokesperson added that vaccine has been found to be safe in clinical trials conducted not only in the SAR and the mainland, but also overseas.